Do you want to read an article? Please log in or register.
Validation of automated lobe segmentation on paired inspiratory-expiratory chest CT in 8-14 year-old children with cystic fibrosis
Pulmonary Fibrosis
Related content
Pulmonary FibrosisBronchi
Quantitative assessment of airway dimensions in young children with cystic fibrosis lung disease using chest computed tomography
Pediatr Pulmonol.
Kuo W, Soffers T, Andrinopoulou ER, Rosenow T, Ranganathan S, Turkovic L, Stick SM, Tiddens HAWM; AREST CF
doi: 10.1002/ppul.23787.
RECOMMENDED
Pulmonary Fibrosis
Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study
Lancet Respir Med.
McNamara JJ, McColley SA, Marigowda G, Liu F, Tian S, Owen CA, Stiles D, Li C, Waltz D, Wang LT, Sawicki GS
doi: 10.1016/S2213-2600(18)30460-0.
Pulmonary Fibrosis
Short-Term Effects of Elastic Chest Wall Restriction on Pulmonary Function in Children with Cystic Fibrosis
Respiration.
Roethlisberger K, Nyilas S, Riedel T, Wolfensberger J, Singer F, Latzin P
doi: 10.1159/000491094.
RECOMMENDED
Pulmonary Fibrosis
Health-related quality-of-life in children with cystic fibrosis aged 5-years and associations with health outcomes
★ 1
Recommended by
Dr Martin Frey, Faculty Member
J Cyst Fibros.
Cheney J, Vidmar S, Gailer N, Wainwright C, Douglas TA, Australasian Cystic Fibrosis Bronchoalveolar Lavage (ACFBAL) study group.
doi: 10.1016/j.jcf.2020.02.022.
CoughPulmonary Fibrosis
The CF-Sputum Induction Trial (CF-SpIT) to assess lower airway bacterial sampling in young children with cystic fibrosis: a prospective internally controlled interventional trial
Ronchetti K, Tame JD, Paisey C, Thia LP, Doull I, Howe R, Mahenthiralingam E, Forton JT
doi: 10.1016/
RECOMMENDED
Pulmonary Fibrosis
Using chest CT scan and unsupervised machine learning for predicting and evaluating response to lumacaftor-ivacaftor in people with cystic fibrosis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Eur Respir J
Campredon A, Battistella E, Martin C, Durieu I, Mely L, Marguet C, Belleguic C, Murris-Espin M, Chiron R, Fanton A, Bui S, Reynaud-Gaubert M, Reix P, Hoang-Thi TN, Vakalopoulou M, Revel MP, Da Silva J, Burgel PR, Chassagnon G, French Cystic Fibrosis Reference Network Study Group.
doi: 10.1183/13993003.01344-2021
Initial acquisition and succession of the cystic fibrosis lung microbiome is associated with disease progression in infants and preschool children
PLoS Pathog.
Muhlebach MS, Zorn BT, Esther CR, Hatch JE, Murray CP, Turkovic L, Ranganathan SC, Boucher RC, Stick SM, Wolfgang MC
doi: 10.1371/
RECOMMENDED
Pulmonary Fibrosis
BAL inflammatory markers can predict pulmonary exacerbations in children with cystic fibrosis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Chest.
Ishak A, Stick SM, Turkovic L, Ranganathan SC, King L, Harrison J, Sly PD, Caudri D, Schultz A, AREST CF.
doi: 10.1016/j.chest.2020.06.044.
RECOMMENDED
CoughPulmonary Fibrosis
Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Hoppe JE, Chilvers M, Ratjen F, McNamara JJ, Owen CA, Tian S, Zahigian R, Cornell AG, McColley SA
doi: 10.1016/S2213-2600(21)00069-2